In this issue of the Journal of Clinical Investigation, researchers led by Ronald Levy at Stanford University found that regulatory T cells that infiltrate tumors express proteins that can be targeted with therapeutic antibodies.
Mice injected with antibodies targeting the proteins CTLA-4 and OX-40 had smaller tumors and improved survival. Moreover, treatment with these antibodies cleared both tumors at the primary site and distant metastases, including brain metastases that are usually difficult to treat. These findings suggest that therapies targeting regulatory T cells could be a promising approach in cancer treatment.
In an accompanying commentary, Cristina Ghirelli and Thorsten Hagemann emphasize that in order for this approach to be clinically relevant, it will be important to show that targeting regulatory T cells in metastatic tumors also blocks growth.
source : http://www.sciencedaily.com/releases/2013/05/130524122004.htm